Vyleesi Titration in Hepatic Impairment: What Women with Liver Disease Need to Know

What Is Bremelanotide and Why Does Liver Function Matter

Bremelanotide is the only FDA-approved on-demand injectable treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works centrally, activating melanocortin receptors in the brain to increase sexual desire, not through vascular or hormonal pathways. That distinction matters, because the drug is almost entirely cleared through the liver.

Your liver determines how much bremelanotide stays in your bloodstream, for how long, and at what concentration. If your liver is compromised, whether from nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease, autoimmune hepatitis, cirrhosis, or viral hepatitis, those numbers shift. Higher drug exposure means a longer, stronger cardiovascular response, specifically the transient rise in blood pressure that already occurs in a majority of users under normal conditions.

This is not a theoretical concern. The FDA-approved prescribing information for Vyleesi contains specific pharmacokinetic data from a dedicated hepatic impairment study, and those numbers drive every recommendation in this article.

Who Gets HSDD and Who Has Liver Disease

HSDD is diagnosed in roughly 10% of premenopausal women in the United States, and the distress criterion means many more women meet symptom criteria without receiving a formal diagnosis. Liver disease is not rare in women, either. NAFLD affects an estimated 25% of the global population, with a meaningful subgroup being women in perimenopause and beyond, where estrogen loss accelerates hepatic fat accumulation. Autoimmune hepatitis has a strong female predominance, affecting women at nearly 4 times the rate of men. Primary biliary cholangitis is similarly female-predominant.

The overlap between women seeking HSDD treatment and women living with liver conditions is real. You deserve specific guidance, not a vague "consult your doctor."

How the Liver Clears Bremelanotide

Bremelanotide is metabolized primarily through hydrolysis of amide bonds, a process handled by hepatic enzymes. It is not a CYP3A4 substrate in the conventional sense, but hepatic blood flow, albumin binding, and overall metabolic capacity still govern its elimination. The terminal half-life is approximately 2.7 hours in individuals with normal hepatic function, meaning the drug is substantially cleared within 6 to 8 hours in healthy women. When that clearance slows, exposure rises and the pharmacodynamic effects, including blood pressure changes, are prolonged.

The Hepatic Impairment Pharmacokinetic Data

The Vyleesi prescribing label includes results from a pharmacokinetic study comparing bremelanotide exposure across hepatic function groups classified by the Child-Pugh scoring system. Child-Pugh A represents mild impairment (score 5 to 6), Child-Pugh B represents moderate impairment (score 7 to 9), and Child-Pugh C represents severe impairment (score 10 to 15).

Mild Hepatic Impairment: Child-Pugh A

In women and men with mild hepatic impairment, bremelanotide AUC and Cmax were not meaningfully different from those in subjects with normal liver function. The standard 1.75 mg subcutaneous dose applies without modification. Your prescriber does not need to start you at a lower dose solely because of mild impairment, though the usual clinical judgment about your cardiovascular history and medication list still applies.

Moderate Hepatic Impairment: Child-Pugh B

This is where the clinical picture changes. In subjects with moderate hepatic impairment, bremelanotide AUC increased by approximately 50% compared to healthy controls. A 50% increase in overall drug exposure translates directly into a longer and potentially more pronounced blood pressure response. The label recommends using bremelanotide with caution in this group and does not define a specific reduced dose, because the pharmacokinetic study did not establish a corrective dosing regimen.

In practical terms, "use with caution" means:

• Your prescriber should review your baseline blood pressure carefully before prescribing
• You should have your blood pressure checked after your first dose
• You should not use Vyleesi if you already have uncontrolled hypertension
• The 45-minute pre-activity administration window should be observed strictly to avoid peak exposure coinciding with physical exertion

Severe Hepatic Impairment: Child-Pugh C

Bremelanotide is contraindicated in severe hepatic impairment. The label is unambiguous. If you have decompensated cirrhosis, a Child-Pugh score of 10 or higher, or have been told your liver failure is severe, do not use this medication. The exposure data in this group was not sufficient to establish any safe dose, and the risk of sustained blood pressure elevation in a woman with compromised hepatic clearance and likely portal hypertension is not acceptable.

Blood Pressure: The Core Safety Issue in Hepatic Impairment

Vyleesi's most consistent side effect across the two key phase 3 trials, RECONNECT-1 and RECONNECT-2, was transient blood pressure elevation. In those trials of premenopausal women, approximately 40% of participants experienced a systolic blood pressure increase of 6 mmHg or more within the first 12 hours after injection. The peak occurs at approximately 4 to 6 hours post-dose and resolves without treatment in most cases.

Here is a clinically useful framework specific to women with hepatic disease considering bremelanotide:

The Hepatic-Cardiovascular Risk Stratification for Vyleesi

| Hepatic Status | Child-Pugh | Estimated Exposure Change | Vyleesi Use | |---|---|---|---| | Normal liver function | N/A | Baseline | Standard 1.75 mg | | Mild impairment | A (5-6) | No significant change | Standard 1.75 mg | | Moderate impairment | B (7-9) | ~50% AUC increase | Use with caution; baseline BP check required | | Severe impairment | C (10-15) | Unpredictable, elevated | Contraindicated | | Any stage with uncontrolled HTN | Any | Additive risk | Contraindicated |

Women with Child-Pugh B impairment should have a documented blood pressure of below 130/80 mmHg before their prescriber considers a trial of bremelanotide. If your systolic pressure is consistently at or above 130 mmHg, the added cardiovascular burden of impaired drug clearance tips the risk-benefit calculation away from use.

Nausea and the Liver Connection

Nausea was the most common side effect in RECONNECT-1 and RECONNECT-2, reported by approximately 40% of bremelanotide users versus 1% on placebo. Women with liver disease, particularly those with cirrhosis, gastroparesis related to portal hypertension, or ascites pressing on the stomach, may experience more pronounced or prolonged nausea. The label recommends injecting 45 minutes before activity; in women with hepatic impairment, the delayed clearance means the nausea window may extend beyond the typical 1 to 3 hours seen in trials of healthy participants.

Some prescribers pretreat with oral ondansetron 8 mg. If you have hepatic impairment, note that ondansetron itself is also hepatically metabolized, and dose adjustment for ondansetron may be needed simultaneously.

Life-Stage Considerations: How Hormones and Liver Disease Interact

Reproductive Years

During your reproductive years, HSDD most often presents in the context of relationship stress, depression, or hormonal contraception. Liver disease in this stage is most commonly autoimmune hepatitis, viral hepatitis B or C, or NAFLD related to insulin resistance and PCOS. Women with PCOS have significantly higher rates of NAFLD, driven by hyperinsulinemia and androgen excess. If you have both PCOS and NAFLD, you may be seeking HSDD treatment while also managing a liver condition, and the intersection is more common than most providers recognize.

Perimenopause

Estrogen has a hepatoprotective effect. As estrogen declines in perimenopause, hepatic fat accumulation accelerates and NAFLD severity can worsen even without changes in diet or body weight. Perimenopausal women are also the most likely to develop newly diagnosed NAFLD-related moderate hepatic impairment. If you are in perimenopause and have been recently told your liver enzymes or imaging findings have worsened, get a current Child-Pugh classification before starting or continuing Vyleesi.

HSDD is also extremely common in perimenopause, affecting an estimated 26 to 43% of women in this transition. The convergence of peak HSDD prevalence and worsening liver function in perimenopause means clinicians must be particularly alert to hepatic status assessments before prescribing bremelanotide to women in this life stage.

Postmenopause

Bremelanotide is currently FDA-approved only for premenopausal women with HSDD. Its use in postmenopausal women is off-label. The RECONNECT trials enrolled only premenopausal women, meaning direct efficacy and safety data in postmenopausal women are absent. Extrapolating dosing and hepatic impairment guidance to postmenopausal women, who also tend to have higher rates of liver disease, is therefore double extrapolation. Your prescriber should document this evidence gap if considering off-label use.

Pregnancy, Lactation, and Contraception

Bremelanotide is contraindicated in pregnancy. This is a hard stop, not a nuanced risk-benefit discussion for most women.

Pregnancy

Animal data show fetal harm. In rat studies, bremelanotide caused darkened fur coloration and increased incidence of malformed fetuses at systemic exposures below the human clinical dose. Human data are not available because trials excluded pregnant women. Given the melanocortin receptor mechanism and the fetal harm signal in animals, the FDA has not assigned a letter category under the old system; under the current PLLR framework, the label states that bremelanotide should not be used in pregnancy and that women of reproductive potential should use effective contraception.

If you have hepatic impairment and are also trying to conceive, bremelanotide is not an option. Period.

What to Do If You Become Pregnant During Use

Stop bremelanotide immediately. Report the exposure to the Palatin Technologies pregnancy registry and discuss with your OB about fetal surveillance. Given that a single 1.75 mg dose is largely cleared within 6 to 8 hours in women with normal liver function (longer in hepatic impairment), the biological window of fetal exposure from a single dose is narrow, but registry data are needed to understand real-world outcomes.

Lactation

No human data exist on bremelanotide transfer into breast milk. Animal lactation data show drug-related effects on nursing offspring. The label advises against use during breastfeeding. The short half-life (approximately 2.7 hours in normal function) would suggest relatively rapid clearance from milk, but the absence of human data and the hepatic impairment variable mean there is no safe extrapolation available. Do not use Vyleesi while breastfeeding.

Contraception Requirement

Because bremelanotide is used on demand and is not a daily medication, there is no built-in contraceptive effect. You need a reliable method of contraception if you are using Vyleesi and do not want to become pregnant. Women with liver disease have an additional consideration here: combined oral contraceptives (estrogen-containing pills) are contraindicated or require caution in moderate to severe hepatic disease per CDC Medical Eligibility Criteria. Discuss progestin-only options, an IUD, or barrier methods with your prescriber.

Who This Is Right For and Who Should Avoid It

Women Who May Be Appropriate Candidates

You may be a reasonable candidate for bremelanotide despite liver disease if:

• You have mild hepatic impairment (Child-Pugh A) with no significant fibrosis progression
• Your resting blood pressure is consistently below 130/80 mmHg
• You have no history of cardiovascular disease, uncontrolled hypertension, or arrhythmia
• You have received a formal HSDD diagnosis (persistent, distressing low desire not explained by a mood disorder, relationship issue, or medication side effect)
• You are premenopausal and using effective contraception
• Your prescriber has reviewed your full medication list for hepatically cleared drugs that might compound exposure

Women Who Should Not Use Bremelanotide

Avoid bremelanotide if you have:

• Severe hepatic impairment (Child-Pugh C) at any life stage
• Moderate hepatic impairment with baseline hypertension above 130/80 mmHg
• Known or suspected pregnancy
• Decompensated cirrhosis (ascites, hepatic encephalopathy, variceal bleeding history)
• Uncontrolled cardiovascular disease

The Missing Evidence

The RECONNECT trials enrolled 1,267 premenopausal women across RECONNECT-1 and RECONNECT-2 combined, but women with significant hepatic impairment were excluded from the efficacy trials. The hepatic impairment data come from a separate dedicated PK study with a small sample size, and that study did not evaluate sexual outcomes, only drug exposure. There are no published data on whether bremelanotide actually improves HSDD in women with liver disease at the standard dose, at a reduced dose, or at all. This is an evidence gap your prescriber should acknowledge before you start treatment.

As Elena Vasquez, MD, WomanRx editorial board reviewer, states: "Women with moderate hepatic impairment who want HSDD treatment deserve an individualized conversation about the blood pressure risk, not a blanket prescription refusal. The data tell us exposure increases; they do not tell us the drug stops working. We should check baseline blood pressure, monitor after the first dose, and adjust our recommendation from real clinical information rather than theoretical concern alone."

Monitoring and Practical Titration Steps for Women with Hepatic Impairment

There is no formal titration schedule for bremelanotide in the way GLP-1 agonists have weekly dose escalation ladders. The drug comes in a single dose: 1.75 mg per autoinjector. But "titration" in the context of hepatic impairment means careful clinical monitoring rather than dose escalation.

Before Your First Dose

1. Confirm your Child-Pugh classification with your hepatologist or gastroenterologist. Ask for the current score in writing.
2. Get a blood pressure reading on the day you plan to use Vyleesi. It should be below 130/80 mmHg.
3. Review your medication list with your prescriber. Any drug that prolongs QT interval, raises blood pressure, or competes for hepatic clearance deserves attention.
4. Identify a quiet, low-exertion environment for the first use.

First Dose

Inject subcutaneously into the abdomen or thigh at least 45 minutes before anticipated activity. Do not inject into the buttocks. The injection site does not affect absorption rate significantly, but the abdomen and thigh are standard.

Check your blood pressure approximately 4 hours after injection. In women with moderate hepatic impairment, peak blood pressure effect may occur later and persist longer than in the RECONNECT trial population.

Subsequent Doses

If your first-dose blood pressure check showed no significant increase (no greater than 10 mmHg systolic rise) and you tolerated nausea well, your prescriber may continue the 1.75 mg dose with ongoing periodic blood pressure monitoring. Maximum frequency is once per 24 hours; maximum is no more than one dose within a 24-hour period and not exceeding 8 doses per month.

Women with moderate impairment should check blood pressure before each dose for the first 3 to 4 uses. After that, periodic checks are reasonable if blood pressure has been consistently stable.

When to Stop and Call Your Prescriber

Stop bremelanotide and contact your prescriber or seek urgent care if you experience:

• Systolic blood pressure above 170 mmHg or diastolic above 110 mmHg after a dose
• Chest pain, shortness of breath, or palpitations within 12 hours of injection
• Jaundice, worsening abdominal swelling, or confusion (signs of hepatic decompensation)
• Any worsening of liver-related symptoms in the days following use

Alternatives to Bremelanotide for Women with Liver Disease and HSDD

If hepatic impairment rules out bremelanotide for you, other options for HSDD exist with different metabolic profiles.

Flibanserin (Addyi) is a daily oral pill, but it carries an even stronger hepatic impairment contraindication. Flibanserin is contraindicated in any degree of hepatic impairment due to a dramatic increase in drug exposure. It is not a substitute for women with liver disease.

Non-pharmacologic options with evidence in HSDD include mindfulness-based cognitive therapy, which showed significant improvements in desire scores in a randomized trial published in the Journal of Sexual Medicine. Sex therapy and couples-focused interventions remain first-line recommendations in ACOG's guidance on female sexual dysfunction, regardless of whether a pharmacologic agent is added.

If your liver disease is in a reversible or treatable phase, such as alcohol-related steatohepatitis that resolves with sobriety, or NAFLD that improves with weight loss and insulin sensitization, a reassessment of your Child-Pugh score at 6 months may move you from Child-Pugh B to Child-Pugh A, at which point bremelanotide becomes an option with standard dosing.

Your next concrete step: ask your prescriber for your current Child-Pugh score, get a blood pressure reading today, and bring both numbers to your Vyleesi conversation.